2510049I19Rik Inhibitors
Chemical inhibitors of 2510049I19Rik can be employed to regulate its activity through various signaling pathways and cell cycle mechanisms. Palbociclib, a CDK4/6 inhibitor, can halt the progression of the cell cycle, which can lead to the inhibition of 2510049I19Rik if it is involved in this process. Similarly, trametinib, as a MEK inhibitor, can block the MEK/ERK pathway, inhibiting 2510049I19Rik if it is a part of this cell signaling route. Rapamycin targets the mTOR pathway, known for its role in cell growth and proliferation, which can inhibit the function of 2510049I19Rik if there is an association with mTOR signaling. LY294002, by inhibiting PI3K, can downregulate the Akt pathway, reducing the activity of 2510049I19Rik if it is implicated in this signaling cascade.
Sorafenib and sunitinib, which target multiple tyrosine protein kinases such as VEGFR, PDGFR, and Raf kinases, can prevent the activation of 2510049I19Rik by obstructing the pathways it may participate in. Erlotinib and gefitinib, selective EGFR inhibitors, can modify the function of 2510049I19Rik through their action on the EGFR pathway. Additionally, U0126 and SB203580, as inhibitors of MEK and p38 MAP kinase respectively, can lead to the inhibition of 2510049I19Rik by interfering with the MAPK/ERK and p38 MAPK pathways. Lastly, SP600125, a JNK inhibitor, can affect the activity of 2510049I19Rik within the JNK signaling pathway, and dasatinib, by inhibiting Src family kinases and Abl, can also affect the functional state of 2510049I19Rik by targeting kinases that are upstream or directly interact with the protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor. By inhibiting CDK4/6, it halts the cell cycle progression, which can lead to the inhibition of 2510049I19Rik if the protein is involved in cell cycle regulation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor. It blocks the MEK/ERK pathway, which is involved in cell signaling related to growth and survival, potentially inhibiting 2510049I19Rik if the protein operates within this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can affect cell growth and proliferation. The inhibition of mTOR can lead to functional inhibition of 2510049I19Rik if it is associated with mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Inhibition of PI3K can lead to the downregulation of the Akt signaling pathway and could inhibit 2510049I19Rik's function if it is part of the PI3K/Akt pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases, such as VEGFR, PDGFR, and Raf kinases. This can lead to the inhibition of 2510049I19Rik by blocking the signaling pathways it may be involved in. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, impacting pathways like VEGFR, PDGFR, and others. Inhibition of these kinases can prevent the activation of 2510049I19Rik if it depends on these pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib selectively inhibits EGFR tyrosine kinase, potentially inhibiting 2510049I19Rik if the protein's function is EGFR pathway-dependent. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor. By targeting EGFR, it could lead to the functional inhibition of 2510049I19Rik if the protein is a component of the EGFR signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, potentially inhibiting the MAPK/ERK pathway. Inhibition of this pathway can lead to the functional inhibition of 2510049I19Rik if it is involved in this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. Inhibition of p38 MAPK can lead to the functional inhibition of 2510049I19Rik if it is a downstream effector in this pathway. | ||||||